CROWN Trial Dashboard
Phase 3 CROWN study — lorlatinib vs crizotinib in ALK-positive NSCLC. The standout number: 3-year progression-free survival of 64% vs 19%. Built as an interactive evidence dashboard covering efficacy, patient profiles, safety data, and patient-reported outcomes — all linked back to source publications.
Challenge
Oncology trials scatter data across PDFs, appendix tables, and journal supplements. The team needed one navigable view that non-statisticians could use to actually understand the evidence — without simplifying it to the point of being misleading.
Solution
Divided the dashboard into thematic sections (efficacy, patient characteristics, safety, PROs). Survival data gets visual charts instead of raw tables. A related-documents section pulls cited publications inline, so you can go from number to source without leaving the page.
Role
Data Analyst
Year
2022